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of tapered stents to accommodate for the size mismatch between
the ICA and the common carotid artery, may exert less expansile
force on the carotid sinus.
In conclusion, patients with “significant baseline comorbid
conditions” may be placed at a greater risk with CAS. It is cur-
rently unclear if CAS can compete successfully with CEA in a
lower risk group. We are grateful to Ouriel et al for supplying us
with this very interesting information.
Karthikeshwar Kasirajan, MD
University of New Mexico
Albuquerque, NM
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Reply
The points raised by Dr Kasirajan and colleagues are quite
interesting and corroborate our own anecdotal findings. We, like
they, have noted quite disturbing drops in heart rate and blood
pressure during balloon dilatation at the carotid bulb. Interestingly,
these changes do not appear to be as profound in patients with
recurrent stenosis, presumably because the carotid sinus nerve has
been disturbed at the time of carotid endarterectomy.
As Dr Kasirajan suggests, these hemodynamic changes are
poorly tolerated by the very category of patients for whom
carotid stenting might be appropriate: those patients with
severe medical comorbidities. It is hopeful that the large ran-
domized studies will help to sort out just the problems that
have been identified by the Albuquerque group. Multivariate
analyses of important clinical endpoints should shed light on
exactly which patients are best served by carotid stenting or
carotid endarterectomy.
Kenneth Ouriel, MD, FACS, FACC
Department of Vascular Surgery
The Cleveland Clinic Foundation
Pepper Pike, Ohio
24/41/118083
doi:10.1067/mva.2002.118083
Regarding “High prevalence of mild
hyperhomocysteinemia in patients with abdominal
aortic aneurysm”
We read with interest the paper by Brunelli et al (J Vasc Surg
2000;32:531-6), as it exactly mirrors our own results published in
abstract form. We have also studied homocysteine in patients with
abdominal aortic aneurysm (AAA) coming to surgery and reported
similar preliminary results in 14 AAA patients with 71% having
homocysteine levels above the 95th percentile and mean homocys-
teine levels higher than in a comparable control group (17.8 vs 11.8
µmol/L; P = .027, Mann-Whitney).1 Since that report we have
recruited a further 46 patients for a total of 60 patients and recently
reported homocysteine levels above the 95th percentile in 48% of
the AAA patients (mean levels, 13.1 vs 10.9 µmol/L; P = .003,
Mann-Whitney).2 One interesting omission from the Brunelli paper
was information on folate status and creatinine levels. These are
both strong predictors of homocysteine levels,3,4 and a significant
proportion of AAA patients will have some degree of renal impair-
ment. Even mild renal impairment can lead to impaired clearance of
homocysteine and raised plasma homocysteine levels. Did the
authors examine folate and creatinine status in their aneurysm
patients, and if so, did these variables influence their results?
Stuart Caldwell, FRCS
Timothy Sykes, FRCS
Damien Mosquera, MD, FRCS
Department of Vascular Surgery
Birmingham Heartlands Hospital
Birmingham, West Midlands, United Kingdom
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